DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cosopt (Dorzolamide Hydrochloride / Timolol Maleate Ophthalmic) - Summary

 
 



COSOPT SUMMARY

What is COSOPT?

COSOPT (dorzolamide hydrochloride-timolol maleate ophthalmic solution) is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent.

COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies).


See all Cosopt indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Cosopt (Dorzolamide / Timolol Ophthalmic)

[Comparative study of the pressure lowering efficacy and variations in the ocular pulse amplitude between fixed combinations of dorzolamide/timolol and brinzolamide/timolol]. [2011.05]
OBJECTIVE: To determine possible differences in the intraocular pressure (IOP) and ocular pulse amplitude (OPA) lowering capacity of the fixed drug combinations dorzolamide/timolol and brinzolamide/timolol... CONCLUSIONS: Both fixed combinations were similarly effective in reducing intraocular pressure and ocular pulse amplitude. Adverse effects related to both treatments were mild and well-tolerated, though itching occurred most frequently in the eyes treated with dorzolamide/timolol. Copyright (c) 2011 Sociedad Espanola de Oftalmologia. Published by Elsevier Espana. All rights reserved.

Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure in a randomized clinical trial. [2010.12]
BACKGROUND: The aim of this study was to compare the efficacy and tolerability of preservative-free (PF) and preservative-containing (PC) formulations of the dorzolamide/timolol fixed combination (COSOPT) in patients with elevated intraocular pressure (IOP)... CONCLUSIONS: In patients with elevated IOP, PF and PC dorzolamide/timolol were equivalent in efficacy for change in trough and peak IOP, and had generally similar tolerability.

Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol. [2010.07]
OBJECTIVE: To compare brimonidine/timolol fixed combination (BrTFC; Combigan *) with dorzolamide/timolol fixed combination (DTFC; Cosopt dagger) in terms of ability to lower intraocular pressure (IOP) in primary open-angle glaucoma (POAG)... CONCLUSION: Reductions from baseline in mean diurnal IOP and morning IOP were greater with BrTFC than with DTFC.

Efficacy and safety of fixed combinations of latanoprost/timolol and dorzolamide/timolol in open-angle glaucoma or ocular hypertension. [2010.07]
AIMS: To compare intraocular pressure (IOP) reductions with fixed-combination (FC) latanoprost/timolol once daily in the evening vsFC dorzolamide/timolol twice daily... CONCLUSIONS: When beta-blocker therapy is inadequate, either FC may achieve the desired IOP level, but FC latanoprost/timolol more often achieves a pressure of <or=16 mm Hg. Both FCs were well tolerated.

Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial. [2010.06]
PURPOSE: To evaluate the additive effect of dorzolamide/timolol fixed combination in patients under monotherapy with latanoprost... CONCLUSIONS: In our sample, dorzolamide 2%/timolol 0.5% fixed combination as add-on therapy in patients with open-angle glaucoma or ocular hypertension under monotherapy with latanoprost with IOP already in mid-teens levels may further enhance pressure reduction.

more studies >>

Clinical Trials Related to Cosopt (Dorzolamide / Timolol Ophthalmic)

The Effects of Cosopt® Vs Xalacom® on Ocular Hemodynamics and Intraocular Pressure (IOP) in Primary Open-angle Glaucoma (POAG) [Recruiting]
Both Cosopt® and Xalatan® plus Timoptic® will significantly lower IOP, however only Cosopt® will demonstrate positive hemodynamic effects. The clinical significance of this will be investigated by examining the ophthalmic and short posterior ciliary arteries to determine the blood supply to the optic nerve head, the site of damage in glaucoma

Patient Preference Comparison of AZARGA Versus COSOPT [Recruiting]
The purpose of this study is to assess patient preference of AZARGA® compared to COSOPT® after one week instillation of each study medication is administered to both eyes in patients with open-angle glaucoma or ocular hypertension.

A Investigator Masked Parallel Comparison of Tolerability of Combigan and Cosopt [Recruiting]

Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data [Recruiting]
To analyze Cosopt® in terms of its effects on ocular perfusion pressure and comprehensive ocular blood flow and in relation to visual field progression and optic nerve structural changes in an ongoing 3 year prospective study involving 120 patients with open angle glaucoma.

COSOPT-S® Treatment Versus Acetazolamide Before Trabeculectomy [Recruiting]
The most common cause of post-trabeculectomy filtration failure is postoperative scarring. Long-term preoperative treatment with local antiglaucoma agents containing preservatives has an increased risk of post-operative scarring of the filtration bleb. Therefore many surgeons prepare their patients for planned trabeculectomy by discontinuing local antiglaucoma drugs, controlling IOP with oral acetazolamide, and treating the eye with local steroids.

Preservative-free COSOPT-S® eye drops b. i.d now provide a possibility to reduce IOP preoperatively with the aim of avoiding postoperative excessive scarring and the known adverse effects of oral acetazolamide while achieving comparable IOP reduction and long-term outcomes.

This study will investigate comparability (non-inferiority) of medical benefits of two different IOP lowering pharmaceutical interventions prior to trabeculectomy comparing COSOPT-S® bid to oral acetazolamide plus dexamethasone.

more trials >>

Reports of Suspected Cosopt (Dorzolamide / Timolol Ophthalmic) Side Effects

Ocular Hyperaemia (12)Loss of Consciousness (6)Cough (6)Drug Ineffective (5)Intraocular Pressure Increased (5)Headache (5)Dizziness (5)Heart Rate Irregular (5)Fear (4)Feeling Cold (4)more >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 2 ratings/reviews, Cosopt has an overall score of 9. The effectiveness score is 8 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
 

Cosopt review by 62 year old female patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   glaucoma
Dosage & duration:   1 drop each eye (dosage frequency: twice a day) for the period of 2years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   The pressure in my eyes decreased with use over a period of four months.
Side effects:   There is a mild burning in my eyes for a couple of minutes after the drops are out in.
Comments:   The drops are administered twice a day approximately 12 hours apart. It is usually necessary to keep eyes closed for a minute or two until the burning subsides.

 

Cosopt review by 53 year old male patient

  Rating
Overall rating:  
Effectiveness:   Considerably Effective
Side effects:   Mild Side Effects
  
Treatment Info
Condition / reason:   High interoccular pressure
Dosage & duration:   One drop each in each eye twice daily (dosage frequency: twice daily) for the period of About 3 years
Other conditions:   none
Other drugs taken:   none
  
Reported Results
Benefits:   Cosopt reduced my occular pressure in both eyes by nearly one third which pleased my eye doctor. The treatment benefits are long term. Reducing occular pressure will prolong eyesight by preserving the optical nerves. Sorry not 50 words.
Side effects:   I suspect it caused increased hair loss (thining) which I became aware of after about two - two and a half years of using the medication. I had hair loss before ever starting medications but it seems like this medicine began increasing the problem. Cosopt burned initially on application and turned the eyes red which cleared up fairly quickly. I am not aware of any other side effect. I switched medications and further explanation is below. If I knew these drugs do cause hair loss it might affect its rating,... but then again it does save the eyes.
Comments:   I had elevated occular pressure that needed to be reduced and my doctor put me on xalatan which caused my eyelashes to begin to thicken and become dark in a couple of months so I had him put me on something else so we went to cosopt. After a time I felt like this was causing increased hair loss so I looked up drug side effects and cosopt was listed as causing hair loss so I had him change it again then I started alphagan p and azopt. My eyes after nearly two months time turned red and never cleared up so the doctor dropped the alphagan p and replaced it with timilol 0.25 percent. The redness quickly went away. Now with azopt in each eye once in the morning and once at bedtime and timilol 0.25 in both in the mornings only my occular pressures have been reduced one to two points lower in each eye than what the cosopt did when taken in the morning and at bedtime. These changes have not stopped the hair loss from occuring even though timilol 0.25 percent has half the timilol in it as the cosopt and is used only once a day in each eye vs cosopts twice a day in each eye. Azopt is reported to cause hair loss and is very similar to the second ingredient in cosopt.

See all Cosopt reviews / ratings >>

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014